AnalystEdge
Sign inGet started
← All stocks

SEPN — Septerna

Median target
$49.5
calls from the last 12 months
Implied return
+25.3%
median target vs. price
Coverage
10 analysts · 10 calls
updated in the last 12 months
Consensus
10/0/0+10 net
Buy / Hold / Sell

Which analysts are behind SEPN's consensus?

See every current rating, price target and the analysts' track records for Septerna — plus the full analyst rankings, firm analytics and screener.

Unlock with PremiumSign in

The consensus above reflects 10 analysts with calls on SEPN updated in the last 12 months. Implied return is the move implied if the consensus target were hit. These are forward-looking predictions, not realized returns. Per-analyst ratings and track records are a Premium feature.

SEPN elsewhere on AnalystEdge

The most recent congressional, executive-branch and insider filings matched to this ticker. Matched by ticker symbol — occasional mismatches are possible. Not investment advice.

Trending today: not in any of today's trending tables (Gaining attention, Losing attention, Most followed)

DateSourceWhoActionDetailAmount
2026-09-01InsidersLong Daniel D.SVP, Drug DiscoveryInsider sale3.3K sh @ $37.83 · planned trade$126K
2026-08-12InsidersRa Capital Management, L.P. +4DirectorInsider sale746.5K sh @ $42.50$31.7M
2026-08-12InsidersRa Capital Management, L.P. +4DirectorInsider sale746.5K sh @ $42.50$31.7M
2026-08-12InsidersThird Rock Ventures V, L.P. +510% ownerInsider sale147.1K sh @ $50.27 · planned trade$7.4M
2026-08-12InsidersThird Rock Ventures V, L.P. +510% ownerInsider sale141 sh @ $51.08 · planned trade$7K
2026-08-11InsidersBhatt ElizabethPresident and COOInsider sale25.0K sh @ $44.00 · planned trade$1.1M
2026-08-03InsidersLong Daniel D.SVP, Drug DiscoveryInsider sale2.3K sh @ $34.68 · planned trade$81K
2026-08-03InsidersLong Daniel D.SVP, Drug DiscoveryInsider sale1.0K sh @ $33.98 · planned trade$34K

More: insider activity · executive branch · trending